Pfizer Inc (PFE) 29.38 $PFE
Amgen edges up on trial results
at Investor's Business Daily - Thu Aug 28, 5:42PM CDT
The biotech firm edged up 0.6% to 138.69 after reporting positive results from its phase three trial of evolocumab in combination with statins in Japanese patients. Amgen's (AMGN) evolocumab is an injectable cholesterol fighter for patients whose...
Most active New York Stock Exchange-traded stocks
AP - Thu Aug 28, 5:02PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Thu Aug 28, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Fed Chair Yellen's assets up 8 percent during 2013
By MARTIN CRUTSINGER - AP - Thu Aug 28, 3:25PM CDT
WASHINGTON (AP) — Federal Reserve Chair Janet Yellen's assets rose in value by at least 8 percent during 2013, raising their total to between $5.3 million and $14.1 million, according to her latest financial disclosure released Thursday.
Midday Glance: Pharmaceuticals companies
AP - Thu Aug 28, 12:19PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Pfizer and Protalix BioTherapeutics Announce FDA Approval of Pediatric Indication for ELELYSO(TM) (taliglucerase alfa) for Injection, for Intravenous Use for the Treatment of Type 1 Gaucher Disease
Business Wire - Thu Aug 28, 12:15PM CDT
Pfizer Inc. (NYSE
FE) and Protalix BioTherapeutics, Inc. (NYSE-MKT LX, TASE LX) announced today that the U.S. Food and Drug Administration (FDA) approved ELELYSO(TM) (taliglucerase alfa) for injection for pediatric patients. ELELYSO is therefore now indicated for long-term enzyme replacement therapy (ERT) for adult and pediatric patients with a confirmed diagnosis of Type 1 Gaucher disease.
3 Reasons for Rite Aid Corporation's Resurgence
Brian Nichols, The Motley Fool - Motley Fool - Thu Aug 28, 12:08PM CDT
In just two years, Rite Aid Corporation 's valuation as a company has increased from $1.2 billion to more than $6 billion today. This epic turnaround is due to three key factors, each of which has been important in taking the company from near...
Early Glance: Pharmaceuticals companies
AP - Thu Aug 28, 9:31AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Global Antifungal Therapeutics (Polyenes, Azoles, Echinocandins, Allylamines) Market:Trends and Opportunities (2014-2019)
M2 - Thu Aug 28, 8:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rnk3h2/global_antifungal) has announced the addition of the "Global Antifungal Therapeutics Market:Trends and Opportunities (2014-2019)" report to their offering. The report titled Global Antifungal Therapeutics Market: Trends and Opportunities (2014-2019) provides an in-depth analysis of global antifungal therapeutics market with focus on antifungal drug classes - Polyenes, Azoles, Echinocandins and Allylamines. This report provides a broad coverage of these classes with detailed analysis of drugs and indications in respective classes. It also assesses the key opportunities and underlying trends in the market and outlines the factors that are and will be driving the growth of the industry in the forecasted period (2014-19). In addition, key players of the industry such as Merck & Co., Inc., Pfizer Inc., Astellas Pharma Inc. and Noble Corporation SCYNEXIS, Inc. are profiled in the report. Over the past several years, there have been high incidences of invasive fungal infections around the globe. In response to this, various antifungal agents with novel action mechanisms, broader action spectrum and fewer side effects have emerged. Growth within global antifungal therapeutics market is driven by high number of cases of fungal infections, rise in number of immune-compromised aged population and various government initiatives in this field. Some of the restraints to market's growth are growing resistance to antifungal drugs, limitations with antifungal drugs, presence of generics and government regulations in pharmaceutical industry. Major trends prevailing in the industry includes growth in resistant strains and Candida & Aspergillus causing maximum fungal infections. Segment Coverage - Polyenes - Azoles - Echinocandins - Allylamines Key Topics Covered: 1. Executive Summary 2. Antifungal Market: An Introduction 3. Global Antifungal Therapeutics Market Analysis 4. Global Antifungal Therapeutics Market Segment by Drug Type 5. Global Antifungal Market: Growth Drivers & Challenges 6. Global Antifungal Market Trends 7. Competitive Landscape: Global Antifungal Market 8. Company Profiles: Global Antifungal Market For more information visit http://www.researchandmarkets.com/research/rn...antifungal
Pfizer's Investigational Vaccine Candidate for Clostridium difficile Receives U.S. Food and Drug Administration Fast Track Designation
Business Wire - Thu Aug 28, 7:00AM CDT
Pfizer Inc. (NYSE FE) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company's investigational Clostridium difficile (C. difficile) vaccine candidate (PF-06425090). Currently in Phase 2 clinical development, the vaccine candidate is designed to prevent C. difficile-associated disease, which can include life-threatening diarrhea and pseudomembranous colitis.
French leader banks on free market to save economy
By JAMEY KEATEN and SYLVIE CORBET - AP - Thu Aug 28, 5:34AM CDT
PARIS (AP) — Facing pitiful poll numbers, Francois Hollande has cast his lot: The French president who once decried global finance and vowed a 75-percent tax on millionaires has quashed dissent from his Socialist government's left flank and appointed a well-heeled former investment banker as his new point man on the economy.
'Fast Money' Recap: What Will a Rising Dollar Do?
at The Street - Thu Aug 28, 4:00AM CDT
The trading panel discussed commodities, J.C. Penney and the latest Apple rumors.
3 Reasons Pfizer Inc.'s Stock Could Fall
Sean Williams, The Motley Fool - Motley Fool - Wed Aug 27, 8:22AM CDT
Pfizer may be the largest pharmaceutical company in the world, but size isn't everything when it comes to developing and selling drugs. Over the past 16 years Pfizer's stock hasn't budged on a nominal basis. That doesn't mean Pfizer's management...
Human Vaccine Technologies Market 2014-2018 - Key Insights into the $43 Billion Industry
M2 - Wed Aug 27, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hl3zqh/human_vaccine) has announced the addition of the "Human Vaccine Technologies Market" report to their offering. The global vaccine market projected to rise to $43.5 billion by 2018, growing at a CAGR of 12.65% Rapid advances in understanding of the immune system and desire of medical community to engineer both preventive and therapeutic vaccines for a wide spectrum of diseases are fueling changes in medicine and in the managed care industry. The growth of global Vaccine market is partly fuelled scientific breakthroughs such as genome sequencing of infectious pathogens, refined understanding of the immune system and its mechanism of response, followed by significant influx of money from public funding bodies, private charity and commercial organizations. Safety, demonstration of sufficiently high efficacy and lack of a consistent evaluation/development pathway are major stumbling blocks for development of new vaccines. The application of modern biological technologies and advances in genomics has resulted in novel concepts like reverse vaccinology, DNA vaccines, recombinant subunit vaccines and non-replicating vectors, some of these concepts have already progressed to advanced clinical trials and new products such as the meningococcal and hepatitis B vaccine. Recently, cancer and certain autoimmune disorders have received attention as targets for both prophylactic and therapeutic vaccines. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Market Analysis 4. Vaccine Technologies Market, by End-User 5. Vaccine Technologies Market, by Type 6. Vaccine Technologies Market, by Class 7. Vaccine Technology Market, by Disease Indication 8. Regional Market Analysis 9. Company Developments 10. Major Company Profiles - Alphavax - Antigen Express, INC. - Bavarian Nordic - Genticel - Glaxo Smithkline PLC - Liquidia Technologies - Merck & CO., INC. - Novartis AG - Pfizer, INC. - Sanofi For more information visit http://www.researchandmarkets.com/research/hl...an_vaccine
Upcoming Conference Schedule, Scholarship, Approved Supplemental New Drug Application, and Technical Updates - Research Reports on Gilead, AbbVie, Pfizer, Express Scripts and Bard
PR Newswire - Wed Aug 27, 8:10AM CDT
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), AbbVie Inc. (NYSE: ABBV), Pfizer Inc. (NYSE: PFE), Express Scripts Holding Company (NASDAQ: ESRX) and C.R. Bard, Inc. (NYSE: BCR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5998-100free.
Will This New Rating Help Pfizer (PFE) Stock Today?
at The Street - Wed Aug 27, 8:09AM CDT
Deutsche Bank starts coverage of Pfizer (PFE) with a 'buy' rating and a $34 price target.
How the Rising Dollar May Impact Your Portfolio - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Tue Aug 26, 8:03PM CDT
These companies could be impacted if the dollar continues to rise.
Merck, Pfizer combining drugs
at Investor's Business Daily - Tue Aug 26, 5:45PM CDT
Merck (MRK) will study its new immunotherapy drug candidate, brolizumab, in combination with Pfizer's (PFE) already-approved Xalkori to treat metastatic lung cancer. The trial is expected to start next year. In Feb. the drug giants announced they...
Amgen edges up on trial results
at Investor's Business Daily - Thu Aug 28, 5:42PM CDT
The biotech firm edged up 0.6% to 138.69 after reporting positive results from its phase three trial of evolocumab in combination with statins in Japanese patients. Amgen's (AMGN) evolocumab is an injectable cholesterol fighter for patients whose...
Most active New York Stock Exchange-traded stocks
AP - Thu Aug 28, 5:02PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Thu Aug 28, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Fed Chair Yellen's assets up 8 percent during 2013
By MARTIN CRUTSINGER - AP - Thu Aug 28, 3:25PM CDT
WASHINGTON (AP) — Federal Reserve Chair Janet Yellen's assets rose in value by at least 8 percent during 2013, raising their total to between $5.3 million and $14.1 million, according to her latest financial disclosure released Thursday.
Midday Glance: Pharmaceuticals companies
AP - Thu Aug 28, 12:19PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Pfizer and Protalix BioTherapeutics Announce FDA Approval of Pediatric Indication for ELELYSO(TM) (taliglucerase alfa) for Injection, for Intravenous Use for the Treatment of Type 1 Gaucher Disease
Business Wire - Thu Aug 28, 12:15PM CDT
Pfizer Inc. (NYSE
FE) and Protalix BioTherapeutics, Inc. (NYSE-MKT LX, TASE LX) announced today that the U.S. Food and Drug Administration (FDA) approved ELELYSO(TM) (taliglucerase alfa) for injection for pediatric patients. ELELYSO is therefore now indicated for long-term enzyme replacement therapy (ERT) for adult and pediatric patients with a confirmed diagnosis of Type 1 Gaucher disease. 3 Reasons for Rite Aid Corporation's Resurgence
Brian Nichols, The Motley Fool - Motley Fool - Thu Aug 28, 12:08PM CDT
In just two years, Rite Aid Corporation 's valuation as a company has increased from $1.2 billion to more than $6 billion today. This epic turnaround is due to three key factors, each of which has been important in taking the company from near...
Early Glance: Pharmaceuticals companies
AP - Thu Aug 28, 9:31AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Global Antifungal Therapeutics (Polyenes, Azoles, Echinocandins, Allylamines) Market:Trends and Opportunities (2014-2019)
M2 - Thu Aug 28, 8:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rnk3h2/global_antifungal) has announced the addition of the "Global Antifungal Therapeutics Market:Trends and Opportunities (2014-2019)" report to their offering. The report titled Global Antifungal Therapeutics Market: Trends and Opportunities (2014-2019) provides an in-depth analysis of global antifungal therapeutics market with focus on antifungal drug classes - Polyenes, Azoles, Echinocandins and Allylamines. This report provides a broad coverage of these classes with detailed analysis of drugs and indications in respective classes. It also assesses the key opportunities and underlying trends in the market and outlines the factors that are and will be driving the growth of the industry in the forecasted period (2014-19). In addition, key players of the industry such as Merck & Co., Inc., Pfizer Inc., Astellas Pharma Inc. and Noble Corporation SCYNEXIS, Inc. are profiled in the report. Over the past several years, there have been high incidences of invasive fungal infections around the globe. In response to this, various antifungal agents with novel action mechanisms, broader action spectrum and fewer side effects have emerged. Growth within global antifungal therapeutics market is driven by high number of cases of fungal infections, rise in number of immune-compromised aged population and various government initiatives in this field. Some of the restraints to market's growth are growing resistance to antifungal drugs, limitations with antifungal drugs, presence of generics and government regulations in pharmaceutical industry. Major trends prevailing in the industry includes growth in resistant strains and Candida & Aspergillus causing maximum fungal infections. Segment Coverage - Polyenes - Azoles - Echinocandins - Allylamines Key Topics Covered: 1. Executive Summary 2. Antifungal Market: An Introduction 3. Global Antifungal Therapeutics Market Analysis 4. Global Antifungal Therapeutics Market Segment by Drug Type 5. Global Antifungal Market: Growth Drivers & Challenges 6. Global Antifungal Market Trends 7. Competitive Landscape: Global Antifungal Market 8. Company Profiles: Global Antifungal Market For more information visit http://www.researchandmarkets.com/research/rn...antifungal
Pfizer's Investigational Vaccine Candidate for Clostridium difficile Receives U.S. Food and Drug Administration Fast Track Designation
Business Wire - Thu Aug 28, 7:00AM CDT
Pfizer Inc. (NYSE
FE) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company's investigational Clostridium difficile (C. difficile) vaccine candidate (PF-06425090). Currently in Phase 2 clinical development, the vaccine candidate is designed to prevent C. difficile-associated disease, which can include life-threatening diarrhea and pseudomembranous colitis. French leader banks on free market to save economy
By JAMEY KEATEN and SYLVIE CORBET - AP - Thu Aug 28, 5:34AM CDT
PARIS (AP) — Facing pitiful poll numbers, Francois Hollande has cast his lot: The French president who once decried global finance and vowed a 75-percent tax on millionaires has quashed dissent from his Socialist government's left flank and appointed a well-heeled former investment banker as his new point man on the economy.
'Fast Money' Recap: What Will a Rising Dollar Do?
at The Street - Thu Aug 28, 4:00AM CDT
The trading panel discussed commodities, J.C. Penney and the latest Apple rumors.
3 Reasons Pfizer Inc.'s Stock Could Fall
Sean Williams, The Motley Fool - Motley Fool - Wed Aug 27, 8:22AM CDT
Pfizer may be the largest pharmaceutical company in the world, but size isn't everything when it comes to developing and selling drugs. Over the past 16 years Pfizer's stock hasn't budged on a nominal basis. That doesn't mean Pfizer's management...
Human Vaccine Technologies Market 2014-2018 - Key Insights into the $43 Billion Industry
M2 - Wed Aug 27, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hl3zqh/human_vaccine) has announced the addition of the "Human Vaccine Technologies Market" report to their offering. The global vaccine market projected to rise to $43.5 billion by 2018, growing at a CAGR of 12.65% Rapid advances in understanding of the immune system and desire of medical community to engineer both preventive and therapeutic vaccines for a wide spectrum of diseases are fueling changes in medicine and in the managed care industry. The growth of global Vaccine market is partly fuelled scientific breakthroughs such as genome sequencing of infectious pathogens, refined understanding of the immune system and its mechanism of response, followed by significant influx of money from public funding bodies, private charity and commercial organizations. Safety, demonstration of sufficiently high efficacy and lack of a consistent evaluation/development pathway are major stumbling blocks for development of new vaccines. The application of modern biological technologies and advances in genomics has resulted in novel concepts like reverse vaccinology, DNA vaccines, recombinant subunit vaccines and non-replicating vectors, some of these concepts have already progressed to advanced clinical trials and new products such as the meningococcal and hepatitis B vaccine. Recently, cancer and certain autoimmune disorders have received attention as targets for both prophylactic and therapeutic vaccines. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Market Analysis 4. Vaccine Technologies Market, by End-User 5. Vaccine Technologies Market, by Type 6. Vaccine Technologies Market, by Class 7. Vaccine Technology Market, by Disease Indication 8. Regional Market Analysis 9. Company Developments 10. Major Company Profiles - Alphavax - Antigen Express, INC. - Bavarian Nordic - Genticel - Glaxo Smithkline PLC - Liquidia Technologies - Merck & CO., INC. - Novartis AG - Pfizer, INC. - Sanofi For more information visit http://www.researchandmarkets.com/research/hl...an_vaccine
Upcoming Conference Schedule, Scholarship, Approved Supplemental New Drug Application, and Technical Updates - Research Reports on Gilead, AbbVie, Pfizer, Express Scripts and Bard
PR Newswire - Wed Aug 27, 8:10AM CDT
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), AbbVie Inc. (NYSE: ABBV), Pfizer Inc. (NYSE: PFE), Express Scripts Holding Company (NASDAQ: ESRX) and C.R. Bard, Inc. (NYSE: BCR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5998-100free.
Will This New Rating Help Pfizer (PFE) Stock Today?
at The Street - Wed Aug 27, 8:09AM CDT
Deutsche Bank starts coverage of Pfizer (PFE) with a 'buy' rating and a $34 price target.
How the Rising Dollar May Impact Your Portfolio - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Tue Aug 26, 8:03PM CDT
These companies could be impacted if the dollar continues to rise.
Merck, Pfizer combining drugs
at Investor's Business Daily - Tue Aug 26, 5:45PM CDT
Merck (MRK) will study its new immunotherapy drug candidate, brolizumab, in combination with Pfizer's (PFE) already-approved Xalkori to treat metastatic lung cancer. The trial is expected to start next year. In Feb. the drug giants announced they...
